+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Apixaban Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • August 2024
  • Region: Global
  • The Business Research Company
  • ID: 5989905
The apixaban market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The escalation observed in the historical period can be credited to a rise in atrial fibrillation cases, the aging demographic, regulatory endorsements and expansions, positive clinical results, and the transition from warfarin to NOACs (novel oral anticoagulants).

The apixaban market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2028 at a compound annual growth rate (CAGR) of 9%. The projected expansion in the forecast period can be ascribed to the sustained prevalence of cardiovascular ailments, heightened awareness and diagnosis rates, burgeoning markets in emerging economies, the aging of the global populace, and alterations in health policies and reimbursements. Key trends anticipated during this period encompass enhancements in drug delivery mechanisms, augmented research and development endeavors, innovation and collaborative initiatives, FDA approval of apixaban, and the integration of digital health and telemedicine services.

The increasing prevalence of cardiovascular disease is anticipated to drive the expansion of the apixaban market. Cardiovascular disease encompasses various heart and blood vessel conditions, such as coronary artery disease, stroke, and heart failure. This rise is attributed to factors such as sedentary lifestyles, poor diets, tobacco use, obesity, high blood pressure, diabetes, and aging populations. Apixaban plays a crucial role in managing cardiovascular disease by reducing the risk of blood clots and preventing conditions such as stroke, deep vein thrombosis, and pulmonary embolism. For example, in January 2024, the American Heart Association reported a slight increase in cardiovascular disease-related deaths in the US compared to the previous year. This underscores the significance of apixaban in addressing this health concern.

Key players in the apixaban market are prioritizing the development of innovative products, including generic anticoagulant medications, to enhance affordability and accessibility for patients. Generic anticoagulant drugs inhibit blood clot formation, thereby reducing the risk of stroke and other cardiovascular events. For instance, in October 2022, Tiefenbacher Pharmaceuticals introduced a generic version of apixaban in Canada, catering to various thrombotic disorders. Through partnerships with generic pharmaceutical companies, they aim to distribute these cost-effective anticoagulant tablets globally, benefiting healthcare systems and patients alike.

In September 2022, SK Capital Partners acquired Apotex Pharmaceutical Holdings Inc., a Canada-based pharmaceutical company specializing in apixaban oral anticoagulants. This acquisition is poised to bring significant changes to the pharmaceutical sector, impacting drug manufacturing, distribution, and research efforts.

Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited.

North America was the largest region in the apixaban market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the apixaban market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Apixaban, classified as a direct oral anticoagulant (DOAC), is an oral medication employed to mitigate the risk of stroke and systemic embolism in individuals afflicted with nonvalvular atrial fibrillation, a type of irregular heartbeat. Furthermore, it is administered to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to forestall DVT, which can culminate in PE, particularly following hip or knee replacement surgery.

Apixaban is available primarily in capsule and tablet forms. Capsules, encasing the medication within a gelatin shell meant for ingestion as a whole, dissolve within the digestive tract to release the active compound. Its utilization spans various applications such as DVT and PE across diverse end-user settings including hospitals, home care, specialty clinics, and others.

The apixaban market research report is one of a series of new reports that provides apixaban market statistics, including apixaban industry global market size, regional shares, competitors with an apixaban market share, detailed apixaban market segments, market trends, and opportunities, and any further data you may need to thrive in the apixaban industry. This apixaban market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The apixaban market consists of sales of generic drugs, oral tablets and blister packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Apixaban Market Characteristics3. Apixaban Market Trends and Strategies
4. Apixaban Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Apixaban Market Size and Growth
5.1. Global Apixaban Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Apixaban Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Apixaban Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Apixaban Market Segmentation
6.1. Global Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Capsule
  • Tablets
6.2. Global Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
6.3. Global Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users
7. Apixaban Market Regional and Country Analysis
7.1. Global Apixaban Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Apixaban Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Apixaban Market
8.1. Asia-Pacific Apixaban Market Overview
(Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Apixaban Market
9.1. China Apixaban Market Overview
9.2. China Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Apixaban Market
10.1. India Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Apixaban Market
11.1. Japan Apixaban Market Overview
11.2. Japan Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Apixaban Market
12.1. Australia Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Apixaban Market
13.1. Indonesia Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Apixaban Market
14.1. South Korea Apixaban Market Overview
14.2. South Korea Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Apixaban Market
15.1. Western Europe Apixaban Market Overview
15.2. Western Europe Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Apixaban Market
16.1. UK Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Apixaban Market
17.1. Germany Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Apixaban Market
18.1. France Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Apixaban Market
19.1. Italy Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Apixaban Market
20.1. Spain Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Apixaban Market
21.1. Eastern Europe Apixaban Market Overview
21.2. Eastern Europe Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Apixaban Market
22.1. Russia Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Apixaban Market
23.1. North America Apixaban Market Overview
23.2. North America Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Apixaban Market
24.1. USA Apixaban Market Overview
24.2. USA Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Apixaban Market
25.1. Canada Apixaban Market Overview
25.2. Canada Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Apixaban Market
26.1. South America Apixaban Market Overview
26.2. South America Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Apixaban Market
27.1. Brazil Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Apixaban Market
28.1. Middle East Apixaban Market Overview
28.2. Middle East Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Apixaban Market
29.1. Africa Apixaban Market Overview
29.2. Africa Apixaban Market, Segmentation by Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Apixaban Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Apixaban Market, Segmentation by End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Apixaban Market Competitive Landscape and Company Profiles
30.1. Apixaban Market Competitive Landscape
30.2. Apixaban Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Johnson & Johnson
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. F. Hoffmann-La Roche Ltd
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Merck & Co. Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Sanofi S.a.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Apixaban Market Other Major and Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. Eli Lilly and Company
31.3. Amgen Inc.
31.4. Viatris Inc.
31.5. Teva Pharmaceutical Industries Ltd.
31.6. Sandoz Group AG
31.7. Daiichi Sankyo Company Limited
31.8. Fresenius Kabi AG
31.9. Hetero Drugs Ltd
31.10. Eisai Co. Ltd
31.11. Sun Pharmaceutical Industries Ltd.
31.12. Aurobindo Pharma Limited
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Cipla Limited
31.15. Aspen Pharmacare Holdings Limited
32. Global Apixaban Market Competitive Benchmarking33. Global Apixaban Market Competitive Dashboard34. Key Mergers and Acquisitions in the Apixaban Market
35. Apixaban Market Future Outlook and Potential Analysis
35.1 Apixaban Market in 2028 - Countries Offering Most New Opportunities
35.2 Apixaban Market in 2028 - Segments Offering Most New Opportunities
35.3 Apixaban Market in 2028 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Apixaban Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on apixaban market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for apixaban? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The apixaban market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Dosage Form: Capsule; Tablets
2) By Application: Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE)
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Sanofi S.A.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Amgen Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Group AG
  • Daiichi Sankyo Company Limited
  • Fresenius Kabi AG
  • Hetero Drugs Ltd
  • Eisai Co. Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd
  • Medichem S.A.
  • Centaur Pharmaceuticals Pvt. Ltd.
  • Simson Pharma Limited
  • OPOCRIN SPA
  • Pinnacle Life Sciences Private Limited

Methodology

Loading
LOADING...

Table Information